Skip to main content

Table 3 Protection of vaccinated A/J mice after a T. cruzi challenge

From: Biological and immunological characterization of recombinant Yellow Fever 17D Viruses expressing a Trypanosoma cruzi Amastigote Surface Protein-2 CD8+T cell epitope at two distinct regions of the genome

Immunogen Days after challenge
live/total animals (% survival) a
AST ± SD
  23dpi 40dpi 60 dpi  
Mock 0/15 (0) 0/15 (0) 0/15 (0) 19.3 ± 1.4
YF 17DD 1/15 (6) 0/15 (0) 0/15 (0) 20.3 ± 1.5
YF17D/E200/Tc 10/15 (66) 0/15 (0) 0/15 (0) 23.7 ± 2.9**
YF17D/NS2B3/Tc 9/15 (60) 3/15 (20) 2/15 (13) 24.8 ± 5.8***
TEWETGQI/Adjv 5/6 (83) 1/6 (16) 0/6 (0) 29.7 ± 7.9***
  1. a Mice were immunized with medium (Mock), YF 17DD, the two recombinant viruses or with TEWETGQI emulsified in Freund's Adjuvant. Four weeks after the second dose, mice were challenged i.p. with 250 bloodstream trypomastigotes. Average survival times (AST) were significant different (*** P < 0.0005, ** P < 0.001, Mann Whitney test).